Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804669 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1 study of Cushing Syndrome and Cushing Disease, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05804669: Recruiting Phase 1 study of Cushing Syndrome and Cushing Disease, sponsored by Crinetics Pharmaceuticals.
NCT05804669 is a Phase 1 study of Cushing Syndrome and Cushing Disease that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 18 participants, below the 178-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05804669, a Phase 1 study of Cushing Syndrome and Cushing Disease, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])
Conditions Studied
Interventions
- DRUG atumelnant
Study Locations (1)
Maryland
- National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT05804669 shows while recruiting
NCT05804669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 178-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which atumelnant is the first listed.
NCT05804669 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05804669 about?
NCT05804669 is a clinical study titled "A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome". A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dep...
What is the current status of trial NCT05804669?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-10-12. Estimated completion is 2026-10.
What conditions does trial NCT05804669 study?
This clinical trial studies the following conditions: Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome.
What interventions are being tested in trial NCT05804669?
The interventions under investigation include: atumelnant (DRUG).
Who is sponsoring clinical trial NCT05804669?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804669 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05804669's enrollment target sits among peer trials
18 9th of 9 higher than 1 of 9 other Cushing Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cushing Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
COMPLETED · Phase 1
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RECRUITING
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
-
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI